Boston Scientific Corporation (BSX) was Initiated by Guggenheim to “Buy”. Guggenheim advised their investors in a research report released on Jun 9, 2016.
Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by RBC Capital Mkts on Apr 28, 2016 to “Outperform”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Stifel on Apr 28, 2016 to “Buy”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Wedbush on Apr 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 23 from a previous price target of $19 .
On the company’s financial health, Boston Scientific Corporation reported $0.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.24. The company had revenue of $1964.00 million for the quarter, compared to analysts expectations of $1912.86 million. The company’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS.
Boston Scientific Corporation closed down -0.12 points or -0.53% at $22.63 with 1,63,28,613 shares getting traded on Tuesday. Post opening the session at $22.74, the shares hit an intraday low of $22.54 and an intraday high of $22.76 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Jun 3, 2016, Timothy A. Pratt (EVP, GC & Chief Admin Officer) sold 24,229 shares at $22.66 per share price. According to the SEC, on Jun 3, 2016, Michael F Mahoney (President & CEO) sold 100,000 shares at $22.69 per share price. On May 12, 2016, Keith D Dawkins (EVP, Global Chief Med. Off.) sold 80,000 shares at $22.15 per share price, according to the Form-4 filing with the securities and exchange commission.
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.